🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

RL

Relmada Therapeutics IncNASDAQ RLMD Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is RLMD undervalued compared to its fair value?

The fair value of RLMD stock is hidden USD. Relative to the market price of 4.06 USD Relmada Therapeutics Inc is hidden.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 10 ful...[More about valuation]

Relmada Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.132 $B

Price:

4.06 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.731

FINANCIALS

Relmada Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.022 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.11 B
0.1 B

Financial Position Analysis

Assets

0.11 B
Current Assets
0.11 B
Total non-current assets

Total current liabilities
0.0084 B
Total non-current liabilities

Cash Flow Statement

-0.012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Relmada Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is RLMD attractive for investment based on fundamental analysis?

RLMD stock rating is hidden. Relmada Therapeutics is a hidden by Eyestock methodology.

Get RLMD Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

RLMD analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for RLMD to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Relmada Therapeutics Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

Relmada Therapeutics Inc dividends

RLMD dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About RLMD stock

About the company Relmada Therapeutics Inc

Market cap $B

0.132

Dividend yield

Shares outstanding

30.0992 B

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

RLMD profile

  • Ticker

    RLMD

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    03 March 2014

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    10

  • City

    Coral Gables

  • Address

    2222 Ponce De Leon Blvd. 3Rd Floor

  • Cusip

    75955J402